NovaBay Pharmaceuticals's three largest insider shareholders as of March 23, 2026 are Fund Lp R01 (TenPercentOwner, 11.36Mn shares), Ventures Iv L.P. Framework (TenPercentOwner, 11.36Mn shares), Michael John Kazley (Chief Executive Officer, 11.36Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Ventures Iv L.P. Framework | 11,361,216 | 0 | 03 Nov, 2025 | |
| Fund Lp R01 | 11,361,216 | 0 | 03 Nov, 2025 | |
| Ventures Iv L.P. Framework | 11,361,216 | 0 | 03 Nov, 2025 | |
| Michael John Kazley | Chief Executive Officer | 0 | 11,361,216 | 03 Nov, 2025 |
| Point Capital Partners Lp Poplar | 204,060 | 0 | 14 Apr, 2025 | |
| Andrew D. Jones | Cfo | 25,492 | 0 | 06 Dec, 2021 |
| Justin Hall | Ceo, Gc And Director | 16,634 | 0 | 16 Sep, 2022 |
| Mijia Wu | 343 | 0 | 15 May, 2023 | |
| Paul E. Freiman | 343 | 0 | 15 May, 2023 | |
| Swan Sit | 343 | 0 | 15 May, 2023 | |
| Yenyou Zheng | 343 | 0 | 15 May, 2023 | |
| Julie Garlikov | 172 | 0 | 15 May, 2023 | |
| Yongxiang Zheng | 172 | 0 | 15 May, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Oct, 2025 | Ventures Iv L.P. Framework | Common Stock | A | 56,806,080 | $0.00 | 11,361,216 | D | C |
| 21 Oct, 2025 | Ventures Iv L.P. Framework | Common Stock | A | 56,806,080 | $0.00 | 11,361,216 | D | C |
| 21 Oct, 2025 | Fund Lp R01 | Common Stock | A | 56,806,080 | $0.00 | 11,361,216 | D | C |
| 21 Oct, 2025 | Michael John Kazley | Common Stock | A | 56,806,080 | $0.00 | 11,361,216 | I | C |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Pre-Funded Warrants (Right to Buy) | A | 2,702,703 | $0.00 | 540,541 | D | P |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Pre-Funded Warrants (Right to Buy) | A | 2,702,703 | $0.00 | 540,541 | D | P |
| 16 Oct, 2025 | Fund Lp R01 | Pre-Funded Warrants (Right to Buy) | A | 2,702,703 | $0.00 | 540,541 | D | P |
| 16 Oct, 2025 | Michael John Kazley | Pre-Funded Warrants (Right to Buy) | A | 2,702,703 | $0.00 | 540,541 | I | P |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series D Non-Voting Convertible Preferred Stock | A | 220,663 | $0.00 | 44,133 | D | J |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series D Non-Voting Convertible Preferred Stock | A | 220,663 | $0.00 | 44,133 | D | J |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series E Non-Voting Convertible Preferred Stock | A | 134,375 | $0.00 | 26,875 | D | J |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series E Non-Voting Convertible Preferred Stock | A | 134,375 | $0.00 | 26,875 | D | J |
| 16 Oct, 2025 | Fund Lp R01 | Series D Non-Voting Convertible Preferred Stock | A | 220,663 | $0.00 | 44,133 | D | A |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series D Non-Voting Convertible Preferred Stock | A | 220,663 | $0.00 | 44,133 | D | J |
| 16 Oct, 2025 | Michael John Kazley | Series D Non-Voting Convertible Preferred Stock | A | 220,663 | $0.00 | 44,133 | I | A |
| 16 Oct, 2025 | Michael John Kazley | Series E Non-Voting Convertible Preferred Stock | A | 134,375 | $0.00 | 26,875 | I | A |
| 16 Oct, 2025 | Fund Lp R01 | Series E Non-Voting Convertible Preferred Stock | A | 134,375 | $0.00 | 26,875 | D | A |
| 16 Oct, 2025 | Ventures Iv L.P. Framework | Series E Non-Voting Convertible Preferred Stock | A | 134,375 | $0.00 | 26,875 | D | J |
| 16 Oct, 2025 | David E. Lazar | Series D Convertible Preferred Stock | D | 441,325 | - | 7,985 | D | S |
| 25 Feb, 2025 | Point Capital Partners Lp Poplar | Common Stock, par value $0.01 per share | A | 25,033 | $0.62 | 146,041 | D | P |